Urton 25 & Urton 50 25 mg, 50 mg Tablet
PDF Leaflet Revision Date: 01 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of overactive bladder (OAB) syndrome.
Dosage (summary)
50 mg once daily; 25 mg for severe renal/hepatic impairment.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- CYP2D6 substrates
- Strong CYP3A inhibitors
Contraindications
- Hypersensitivity
- Severe renal impairment
- Severe hepatic impairment
- Uncontrolled hypertension
Common side effects
- Urinary tract infection
- Tachycardia
- Dizziness
Counselling Points
- Take once daily with liquids
- Monitor blood pressure
- Avoid in pregnancy and breastfeeding
Serious warnings
- May increase blood pressure
- Caution in QT prolongation
Important Disclaimer
The Urton 25 & Urton 50 25 mg, 50 mg Tablet professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
